The discovery platform is key to a growing pipeline of novel candidate compounds. Our current portfolio focuses on solid cancers, which represent about 90 percent of adult cancer cases.

​

• Seven novel candidate compounds shown to inhibit SERCA;

• Candidates show powerful anti-cancer effects through combination treatment with standard cancer therapies;

• Active ongoing research on candidate compounds for stand-alone therapeutic drugs on refractory cancers.

​

​